Biblio

Author Title Type [ Year

]

Filters: Author is Feng, Sizhou [Clear All Filters]

2024

Zhang X, Zhao X, Chen S, Hao M, Zhang L, Gong M, Shi Y, Wei J, Zhang P, Feng S, et al. Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients. Bone Marrow Transplant. 2024.

Shao W, Wang Y, Liu L, Ren Y, Wang J, Cui Y, Liu J, Zhang X, Zhang S, Liu S, et al. Combining serum microRNAs and machine learning algorithms for diagnosing infectious fever after HSCT. Ann Hematol. 2024.

Cao Y, Wang M, Wang F, Guo W, Ma Y, Li X, He Y, Pang A, Zhang R, Zhai W, et al. Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study. Chin Med J (Engl). 2024.

Pei X, Liu L, Wang J, Guo C, Li Q, Li J, Ren Q, Ma R, Zheng Y, Zhang Y, et al. Exosomal secreted SCIMP regulates communication between macrophages and neutrophils in pneumonia. Nat Commun. 2024;15(1):691.

Li J, Liu Y, Wang J, Wang Y, Pang A, Yang D, Chen X, Zhang R, Wei J, Ma Q, et al. Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation. Sci Rep. 2024;14(1):5178.

Zhang H, Zheng X, Guo W, Xia Y, Zhang R, Zhai W, Chen X, Ma Q, Yang D, Wei J, et al. Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system. Exp Hematol Oncol. 2024;13(1):16.

Gao H, Wang J, Zheng X, Pei X, Zheng Y, Zhai W, Zhang R, Chen X, Ma Q, Wei J, et al. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort. Front Cell Infect Microbiol. 2024;14:1324019.

2023

Shen Y, Sun J, Yang D, Feng S. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion. Blood Sci. 2023;5(4):274-276.

Shen Y, Zhang T, Zhang L, Zhen S, Chen Z, Zhang R, Yang D, Wei J, He Y, Jiang E, et al. Allogeneic stem cell transplantation can prolong the survival of patients with NUP98-rearranged acute myeloid leukemia. Bone Marrow Transplant. 2023.

Guo W, Liu X, Wang M, Liu J, Cao Y, Zheng Y, Zhai W, Chen X, Zhang R, Ma Q, et al. Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia. Hematology. 2023;28(1):2205739.

Chen X, Ma Y, Zhang R, Zhai W, Ma Q, Pang A, Yang D, Wei J, He Y, Song Z, et al. Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation. Hematology. 2023;28(1):2212943.

Zhang L, Zhen S, Shen Y, Zhang T, Wang J, Li J, Lin Q, Xiao Z, Zheng Y, Jiang E, et al. Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options. Ann Clin Microbiol Antimicrob. 2023;22(1):41.

Cao Y, Gong X, Feng Y, Wang M, Hu Y, Liu H, Liu X, Qi S, Ji Y, Liu F, et al. The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases. Am J Hematol. 2023.

Zheng X, Gao H, Lu N, Wang M, Zhang H, Zheng Y, Shen B, Cao Y, Chen X, Zhai W, et al. Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Ann Hematol. 2023.

Chen X, Zheng X, Lu N, Zhang R, Zhai W, Ma Q, Pang A, Yang D, Wei J, He Y, et al. Explorations of post-gDLI low-dose cyclophosphamide for preventing severe aGVHD. Int Immunopharmacol. 2023;125(Pt A):111165.

Chen X, Ma Q, Pang A, Yang D, Liang C, Liu Q, Liu X, Zheng X, Jiang E, Han M, et al. Hematopoietic stem cell transplantation from an infected SARS-CoV2 haploidentical donor: A case report. IDCases. 2023;34:e01913.

Fan Y, Teng Y, Liu FTong, Ma F, Hsu AY, Feng S, Luo HR. Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay. J Vis Exp. 2023;(195).

Shen Y, Yang D, Zhang R, Chen X, Ma Q, Wei J, Zhai W, Pang A, He Y, Jiang E, et al. The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation. Front Oncol. 2023;13:1256043.

Lv M, Liu L, He Y, Yang D, Ma Q, Pang A, Zhai W, Wei J, Huang Y, Chen X, et al. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease. Br J Haematol. 2023.

Chen Y, Huang X, Qiu H, Cheng L, Yu Y, Ma X, Feng S, Li Q, Wu D, Huang W, et al. Physicians' knowledge of invasive fungal disease in China. Mycoses. 2023.

Zhao X, Hao M, Zhang X, Wei J, Feng S, He Y, Jiang E, Han M. Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report. Onco Targets Ther. 2023;16:1055-1059.

Cao Y, Zheng X, Zhang H, Wang M, Guo W, Chen X, Zhai W, Wei J, Yang D, Huang Y, et al. Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2023.

Chen S, An L, Han J, Zheng X, Zhang X, Li G, Zhang Y, Cao W, Lv M, Yang D, et al. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review. Transpl Immunol. 2023:101895.

Shen Y, Zhang L, Zhang X, Zhang T, Jiang E, Feng S, He Y, Zhang R. Treatment with the combination of rituximab and intravenous γ globulin is effective in promoting engraftment in donor specific antibody positive patients receiving myeloablative conditioning haploidentical stem cell transplantation. Transplant Cell Ther. 2023.

2022

Zhao F, Shi Y, Chen X, Zhang R, Pang A, Zhai W, Yang D, He Y, Feng S, Zhang P, et al. Higher Dose of CD34 cells Promotes Early Reconstitution of Natural Killer Cells and Is Associated with Better Outcomes After Unmanipulated Hematopoietic Stem Cell Transplantation for Myeloid Malignancies. Transplant Cell Ther. 2022.

Pages